Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019220 | 0.98 | — | — | |
| SCHEMBL6948184 | 0.98 | — | — | |
| SCHEMBL6948180 | 0.98 | — | — | |
| Bromide SCHEMBL9272773 | 0.95 | — | — | |
| Acetic Acid SCHEMBL27856182 | 0.87 | HTR2C (0.38) | — | |
| SCHEMBL28319120 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL2376191 | 0.79 | CA1 (0.48) | — | |
| Tert-Butyl Formate SCHEMBL27988951 | 0.78 | TDP1 (0.42) | — | |
| SCHEMBL17644091 | 0.76 | — | — | |
| SCHEMBL15927307 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4490151-A1 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | Incyte Corporation (US) | 2025-01-15 | — | — | EP | disclosed |
| CN-119072470-A | Solid forms, salts and methods of preparation of CDK2 inhibitors | 因赛特公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240360126-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2024-10-31 | — | — | US | disclosed |
| EP-4405051-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| CN-118076604-A | Pyrazolo [3,4-b ] pyridine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023172921-A1 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | INCYTE CORPORATION (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230279004-A1 | SOLID FORMS, SALTS, AND PROCESSES OF PREPARATION OF A CDK2 INHIBITOR | INCYTE CORPORATION | 2023-09-07 | — | — | US | disclosed |
| WO-2023046806-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-03-30 | — | — | WO | disclosed |
| CN-113248491-B | Substituted indole urea derivatives, synthesis method and application thereof | 中国科学院上海药物研究所 | 2022-02-25 | — | — | CN | disclosed |
| CN-113248491-A | Substituted indole urea derivatives, synthesis method and application thereof | 中国科学院上海药物研究所 | 2021-08-13 | — | — | CN | disclosed |
| EP-1565461-A2 | ANTIBACTERIAL SUBSTITUTED CYANOMETHYL(ENE)PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Patel, Mahesh V. (IN) | 2005-08-24 | — | — | EP | disclosed |
| US-20040157831-A1 | Therapeutic 5-HT ligand compounds | PHARMACIA & UPJOHN COMPANY | 2004-08-12 | — | — | US | disclosed |
| EP-1414826-A1 | THERAPEUTICALLY USEFUL TETRACYCLIC LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6720316-B2 | A TRICYCLIC HEXAHYDROAZEPINOINDOLE AND INDOLINE DERIVATIVES, FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-20040063954-A1 | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites | WOCKHARDT LIMITED | 2004-04-01 | — | — | US | disclosed |
| WO-2004007489-A2 | ANTIBACTERIAL SUBSTITUTED CYANOMETHYL (ENE) PIPERIDINOPHENYL OXAZOLIDINONES, PROCESS OR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WOCKHARDT LIMITED (IN) | 2004-01-22 | — | — | WO | disclosed |
| US-20030050300-A1 | Therapeutic 5-HT ligand compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-13 | — | — | US | disclosed |
| WO-2003014125-A1 | THERAPEUTICALLY USEFUL TETRACYCLIC LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-02-20 | — | — | WO | disclosed |
| US-6342511-B1 | RACEMIC, ENANTIOMORPHS AND DIASTERIOMORPHS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-01-29 | — | — | US | disclosed |
| US-5846980-A | N-(benzhydryloxyalkyl)-4-(carboxy/carbamoyl methyl)-piperidine derivatives as antidepressants | COOPERATION PHARMACEUTIQUE FRANCAISE (FR) | 1998-12-08 | — | — | US | disclosed |